Alexion Pharmaceuticals Downgraded by Goldman Sachs Group Inc. to Neutral (ALXN)
Alexion Pharmaceuticals (NASDAQ:ALXN) was downgraded by investment analysts at Goldman Sachs Group Inc. from a “buy” rating to a “neutral” rating in a note issued to investors on Monday, TheFlyOnTheWall.com reports.
A number of other firms have also recently commented on ALXN. Analysts at Piper Jaffray initiated coverage on shares of Alexion Pharmaceuticals in a research note to investors on Tuesday, November 26th. They set an “overweight” rating and a $172.00 price target on the stock. Separately, analysts at Zacks downgraded shares of Alexion Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Friday, November 15th. They now have a $126.00 price target on the stock. Finally, analysts at Oppenheimer raised their price target on shares of Alexion Pharmaceuticals from $115.00 to $125.00 in a research note to investors on Friday, October 25th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and thirteen have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $128.50.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded down 1.41% on Monday, hitting $129.86. The stock had a trading volume of 1,088,027 shares. Alexion Pharmaceuticals has a one year low of $81.82 and a one year high of $134.27. The stock’s 50-day moving average is $125.7 and its 200-day moving average is $114.1. The company has a market cap of $25.462 billion and a P/E ratio of 74.50.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, October 24th. The company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.04. The company had revenue of $400.40 million for the quarter, compared to the consensus estimate of $395.10 million. During the same quarter in the previous year, the company posted $0.60 earnings per share. The company’s revenue for the quarter was up 36.1% on a year-over-year basis. Analysts expect that Alexion Pharmaceuticals will post $3.04 EPS for the current fiscal year.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.